Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: a retrospective study
Clinics
; 65(6): 613-619, 2010. tab, ilus
Article
em En
| LILACS
| ID: lil-553967
Biblioteca responsável:
BR1.1
ABSTRACT
INTRODUCTION:
Cerebral palsy is the most common cause of physical disability in children. Spasticity is a disabling clinical symptom that is prevalent among patients suffering from cerebral palsy. The treatment of spasticity with botulinum toxin type A (BTX-A) is a well-established option in the interdisciplinary management of spasticity, providing focal reductions in muscle tone in cerebral palsy patients.OBJECTIVE:
The aim of this retrospective study was to describe the effect of multilevel BTX-A injections in the lower extremities, focusing mainly on gross motor function and functional status in cerebral palsy patients.METHODS:
Data from 71 cerebral palsy patients (64 percent male, 36 percent female, mean age 6.7 ±3.2 years) were analyzed retrospectively. We used the Ashworth and Tardieu scales to evaluate the degree of spasticity. Motor function was measured by the Gross Motor Function Measure (GMFM-88), and functional status was classified by the Gross Motor Function Classification System (GMFCS I-V). Multilevel BTX-A injections were applied after sedation and with electrostimulation guidance. The evaluations were repeated every three months, and the patients were followed for six months.RESULTS:
We found that the Ashworth and Tardieu scores decreased significantly at the three-month evaluation (p<0.05) but not at the six-month evaluation (p>0.05). Although the improvement in spasticity was not maintained at the six-month evaluation, GMFM-88 scores increased significantly at the three- and six-month assessments. GMFSC levels showed no change in the three- and six-month assessments.CONCLUSION:
We believe that a single multilevel BTX-A injection reduces spasticity and improves motor function in children with cerebral palsy.Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Paralisia Cerebral
/
Toxinas Botulínicas Tipo A
/
Fármacos Neuromusculares
Tipo de estudo:
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Clinics
Assunto da revista:
MEDICINA
Ano de publicação:
2010
Tipo de documento:
Article